Stock News

The FDA has accepted the ADH1 application for priority review, with a May 8, 2027 target decision date.

NexGen describes delivery as several months ahead of planned installation; the post does not give dates for dispatch or installation.

The equipment will supply concrete for shaft pads and the mill terrace, but NexGen did not report commissioning or a first pour.

The FDA accepted the uveitic macular edema application after MEERKAT met its primary endpoint and SANDCAT did not.

The 10-year A901 agreement lifts secured capacity to 273.5 MW; Bitdeer reported no signed customer offtake there as of Oct. 8.

The Oct. 9 joint filing asks the D.C. Circuit to adopt Feb. 19, 2027, as the final briefing date for three consolidated petitions for review.

The total rose 19 per cent from the June quarter but includes 6,904 tonnes of previously stockpiled fines designated for sale.

The oral drug's label covers immunocompromised adults whose lesions failed standard antivirals, with U.S. availability expected before the end of 2026.

Mkango says its Pforzheim recycling plant is being commissioned with planned minimum initial capacity of about 100 tonnes of magnets and alloys a year.

The miner's pure bitcoin holdings remained at zero on Oct. 9, compared with 292.3 BTC produced and sold a week earlier.

EXCALIBER-RRMM met its second primary endpoint, with median progression-free survival estimated at 42 months versus 20 months.

Third-quarter output of 3.44 million silver ounces leaves nine-month production at 72 per cent of the revised annual guidance midpoint.

The Oct. 8 label covers IV treatment from age two and Hybreza injections from age 12 for patients weighing at least 40 kilograms.

The initial capacity could bring US$90M over 60 months once energized; the US$450M expansion scenario remains conditional.

The Oct. 9 filing follows a July deal to issue 0.015383618 Vireo share per eligible Planet 13 share, subject to shareholder and regulatory approvals.

The FDA reviewed data from 12 cancer types, but Natera disclosed no performance figures or date for a marketing submission.

The nonbinding proposal covers an unnamed operating site with about 6 MW of power today and a possible expansion to 36 MW.

ICONIC-LEAD's two-year skin clearance results set a longer follow-up point for Alumis's investigational oral psoriasis drug.

Average operating hashrate fell to 36.0 EH/s while holdings declined to 13,530 bitcoin at Sept. 30.

BTQ will map a post-quantum transition and test its signing network with Korean banks, but the Oct. 9 release discloses no fee or trial date.

WELTRUZA is expected in three strengths in the coming weeks, with no post-injection observation required, Teva says.

The Oct. 8 cash deal lifts its Canadian network to 234 stores, including 93 in Alberta, and the shop is set to become a Canna Cabana.

The continuous-treatment cohort showed symptom gains as Alumis targets a fourth-quarter U.S. drug application.

Blanket produced 17,030 ounces in the September 2026 quarter as compressor delays and retained gold pushed cost guidance higher.

WISeQey and SEALSQ would receive 66.61 million shares as the quantum vehicle targets a first-quarter 2027 Nasdaq listing.

At K-Ozek, hole EL26039 returned 22.8 metres grading 5.37 grams per tonne gold from 124.2 metres downhole.

Kaiser produced 6,263 gold ounces in the September quarter; Henty remained below target and the company plans to clear its Auramet loan in October.

The non-brokered placement issued 73.2 million units at C$0.18, while a separate transaction settled secured debentures with Delbrook funds.

A PEA models 36.8 million payable pounds of annual copper equivalent output and a C$8.6 million net initial funding need.

The Oct. 8 preliminary Form F-3 covers note conversions and warrants; selling holders would receive proceeds from resales.

Guardant360 CDx can identify ESR1 mutations before progression in eligible advanced breast cancer; Guardant's Oct. 8 release gave no European payer terms.

The 60-month term starts at service readiness; a separate 32-server purchase is priced at approximately US$18.8M.

A property memorandum links a Washington Avenue retail renovation to Trulieve TX Inc.; a Texas accessibility review does not authorize cannabis sales.

The company says its 3-MMC claims cover dyskinesia treatment alone and with PEA, but gave no publication number or grant timetable.

Funding beyond the undisclosed initial obligation depends on future appropriations as DARPA tests IonQ systems through 2029.

The Oct. 6 departure took effect immediately, while SNDL's board page still listed Cannell among seven directors on Oct. 7.

First reading starts a hearing process for Bell's conditional land purchase; Bell proposes up to 900 MW of additional power.

Saxony-Anhalt licensed new production areas in Leuna, but Aurora gave no tonnage or timetable for deliveries from the expanded site.

Gross margin widened to 30 per cent, but cannabis revenue declined; Tilray retained its fiscal 2027 adjusted EBITDA target.

A European Radiology paper tested DeepHealth's MRI risk score on 787 men; simulated biopsy savings have yet to be shown in practice.